Oragenics Inc (OGEN) Stock Price, Quote & News

Company Profile

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplif...

Industry: Biotechnology

Sector: Healthcare

Phone: 813 286 7900

Fax: 813 286 7900

Website: www.oragenics.com

Address:

1990 Main Street, Suite 750, Sarasota, United States

RocketQueen Dec. 4 at 9:10 PM

$OGEN price and volume are continually decaying. Expect cheap shares in the .30-.40 range soon. Garbage biotechs like OGEN live in the .30 range, and that's why it's never worth it to buy.

0 · Reply

SXCross Dec. 4 at 4:05 PM

$OGEN The pure cash value per share is over $2.

0 · Reply

RocketQueen Dec. 4 at 3:16 PM

$OGEN over priced . The next offering will pull this down to near non compliance.

0 · Reply

Stock_Catcher Dec. 4 at 2:56 AM

Money Thursday Watchlist Pt 9 $BBBY $ETHZ $OGEN $OPGN $DRUG Let's Ride Tomorrow 📈

0 · Reply

sincosine Dec. 3 at 6:23 PM

$OGEN garbage 🗑️ stock and definitely management is a massive scam period !

0 · Reply

NMax Dec. 3 at 2:16 PM

$OGEN continuing to add! 🤑🤑🤑

0 · Reply

Gerante911TurboS Dec. 3 at 4:04 AM

$OGEN yep, this will not end well.

0 · Reply

RocketQueen Dec. 2 at 6:46 PM

$OGEN the next offering will likely be in the .40 range.

0 · Reply

RocketQueen Dec. 2 at 6:44 PM

$OGEN janet will do another cash raise soon. So, might as well wait to get cheaper shares in the thirty cent range. At that point, it will be near noncompliance again ---- this is nothing but a worthless money shredder.

0 · Reply

Jimmymalik123 Dec. 2 at 4:59 PM

$OGEN trust me when I say this … even if oragneics drug cures cancer this shit stock not moving anywhere! It’s been diluted so much that even if it rises by 1000% won’t mean nothing!

0 · Reply

Oragenics Q3 2025 Shareholder Update

Oct 21, 2025, 8:00 AM EDT - 6 weeks ago

Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Oct 7, 2025, 8:30 AM EDT - 2 months ago

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Aug 11, 2025, 8:45 AM EDT - 4 months ago

Oragenics Q2 2025 Shareholder Update

Jul 16, 2025, 8:39 AM EDT - 5 months ago

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

Jul 2, 2025, 4:15 PM EDT - 5 months ago

Oragenics Completes Approximately $16.5 Million Offering

Jul 1, 2025, 8:31 AM EDT - 5 months ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

May 13, 2025, 8:30 AM EDT - 7 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 12, 2025, 8:30 AM EDT - 7 months ago

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Apr 7, 2025, 4:30 PM EDT - 8 months ago

Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit

Mar 27, 2025, 8:30 AM EDT - 9 months ago

Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress

Mar 18, 2025, 5:33 PM EDT - 9 months ago

Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Mar 6, 2025, 9:30 AM EST - 9 months ago

Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)

Feb 25, 2025, 8:30 AM EST - 10 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Feb 11, 2025, 8:30 AM EST - 10 months ago

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Feb 5, 2025, 8:15 AM EST - 10 months ago

Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025

Jan 21, 2025, 8:15 AM EST - 11 months ago

Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

Dec 16, 2024, 8:09 AM EST - 1 year ago

Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference

Oct 18, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation

Oct 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Announces Closing of Public Offering

Sep 4, 2024, 8:36 AM EDT - 1 year ago

Oragenics, Inc. Announces Pricing of Public Offering

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Aug 16, 2024, 4:30 PM EDT - 1 year ago

Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study

Aug 8, 2024, 8:45 AM EDT - 1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

Jun 24, 2024, 6:43 PM EDT - 1 year ago

Oragenics, Inc. Announces Proposed Public Offering

May 22, 2024, 8:00 AM EDT - 1 year ago

Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

May 17, 2024, 8:00 AM EDT - 1 year ago

Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine

Apr 19, 2024, 5:50 PM EDT - 1 year ago

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Apr 1, 2024, 9:05 AM EDT - 1 year ago

Oragenics, Inc. Files 10K and Provides Company Update

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Mar 5, 2024, 7:45 AM EST - 1 year ago

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Mar 1, 2024, 4:04 PM EST - 1 year ago

Oragenics Announces Closing of Public Offering

Feb 27, 2024, 9:25 PM EST - 1 year ago

Oragenics Announces Pricing of Public Offering

Feb 27, 2024, 4:33 PM EST - 1 year ago

Oragenics Announces Proposed Public Offering

Feb 12, 2024, 4:41 PM EST - 1 year ago

Oragenics, Inc. Announces Leadership Transition

Feb 7, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement

Feb 5, 2024, 8:00 AM EST - 1 year ago

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Jan 23, 2024, 5:34 PM EST - 2 years ago

Oragenics Announces Termination of At-The-Market Offering Program

Jan 2, 2024, 7:30 AM EST - 2 years ago

Oragenics Completes Acquisition of Odyssey Health's Neurological Assets

Nov 2, 2023, 7:00 AM EDT - 2 years ago

Oragenics Issues Update to Shareholders

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

Oct 18, 2023, 8:30 AM EDT - 2 years ago

Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors

Oct 5, 2023, 6:30 AM EDT - 2 years ago

Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Sep 29, 2023, 4:00 PM EDT - 2 years ago

Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets

Aug 7, 2023, 8:30 AM EDT - 2 years ago

Oragenics, Inc. Announces Private Placement

RocketQueen Dec. 4 at 9:10 PM

$OGEN price and volume are continually decaying. Expect cheap shares in the .30-.40 range soon. Garbage biotechs like OGEN live in the .30 range, and that's why it's never worth it to buy.

0 · Reply

SXCross Dec. 4 at 4:05 PM

$OGEN The pure cash value per share is over $2.

0 · Reply

RocketQueen Dec. 4 at 3:16 PM

$OGEN over priced . The next offering will pull this down to near non compliance.

0 · Reply

Stock_Catcher Dec. 4 at 2:56 AM

Money Thursday Watchlist Pt 9 $BBBY $ETHZ $OGEN $OPGN $DRUG Let's Ride Tomorrow 📈

0 · Reply

sincosine Dec. 3 at 6:23 PM

$OGEN garbage 🗑️ stock and definitely management is a massive scam period !

0 · Reply

NMax Dec. 3 at 2:16 PM

$OGEN continuing to add! 🤑🤑🤑

0 · Reply

Gerante911TurboS Dec. 3 at 4:04 AM

$OGEN yep, this will not end well.

0 · Reply

RocketQueen Dec. 2 at 6:46 PM

$OGEN the next offering will likely be in the .40 range.

0 · Reply

RocketQueen Dec. 2 at 6:44 PM

0 · Reply

Jimmymalik123 Dec. 2 at 4:59 PM

$OGEN trust me when I say this … even if oragneics drug cures cancer this shit stock not moving anywhere! It’s been diluted so much that even if it rises by 1000% won’t mean nothing!

0 · Reply

TritiumH3 Dec. 2 at 3:57 AM

$OGEN load up for another lesson 😜

0 · Reply

RocketQueen Dec. 2 at 2:21 AM

$OGEN publicly traded scam.

0 · Reply

golfandsurf Dec. 1 at 10:17 PM

$OGEN we have all been bloodied and beaten from this stock for some time. With that being said........ i feel some good news gets dropped this week. Wont make us all whole but will be positive vibes going into 2026. Imo drops tomorrow or Wednesday

0 · Reply

RocketQueen Dec. 1 at 8:10 PM

$OGEN contracting in all dimensions and headed for non compliance with NYSE again soon. No labs, no employees, no real products and no offices. Just shareholder updates written in AI that trashes previous leadership and more PONZI scams.

0 · Reply

SXCross Dec. 1 at 4:56 PM

$OGEN We need the IND submission, then it will rise to 10 USD.

2 · Reply

RocketQueen Dec. 1 at 4:48 PM

$OGEN headed for a new ATL. I've been warning you all for months. This is a value shredder.

0 · Reply

SXCross Dec. 1 at 4:32 PM

$OGEN There is no recovery in this stock. Not a buy for me right now. The losses are too great.

0 · Reply

NMax Dec. 1 at 2:51 PM

$OGEN accumulating more this week!!! 🤑🤑🤑

0 · Reply

RocketQueen Dec. 1 at 3:40 AM

$OGEN no reason to buy now as slow bleed to .20 again.

0 · Reply

SXCross Nov. 28 at 6:03 PM

$OGEN Always these short sellers

0 · Reply

NMax Nov. 28 at 4:45 PM

$OGEN Added! Have a great weekend Seeya next week for more accumulation!! 🤑🤑🤑

0 · Reply

sincosine Nov. 28 at 4:21 PM

$OGEN where is POS NMAX? Still buying ? Jackass! Pumper working with the scammer’s management

0 · Reply

Market Cap	3.56M
Revenue (ttm)	0.00
Net Income (ttm)	-10.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	52,615
Avg Vol	117,714
Day's Range	N/A - N/A
Shares Out	4.17M
Stochastic %K	13%
Beta	0.92
Analysts	Strong Buy
Price Target	$2.00